THIS PROJECT WILL EVALUATE ANTIBODY-MEDIATED, POLYMER-BOUND YTTRIUM-90 AS A CANCER THERAPY AGENT.

THIS PROJECT WILL EVALUATE ANTIBODY-MEDIATED, POLYMER-BOUND YTTRIUM-90 AS A CANCER THERAPY AGENT. ANTIBODIES WILL BE COUPLED THROUGH ONE COVALENT BOND TO A SMALL POLYLYSINE UNIT. THE LATTER WILL CARRY, VIA A BIFUNCTIONAL COUPLING AGENT, MOLECULES OF THE TRIVALENT METAL CHELATING SIDEROPHORE, DEFEROXAMINE. EACH DEFEROXAMINE WILL BE COMPLEXED WITH A SINGLE ATOM OF YTTRIUM-90, A HIGH ENERGY BETA-EMITTER. THE OPTIMUM NUMBER OF DEFEROXAMINES, BINDABLE TO THE EPSILON AMINO GROUPS WILL BE DETERMINED AND UNREACTED AMINO GROUPS BLOCKED TO ENSURE NONINTERFERENCE IN ANTIBODY CONJUGATION. THE POLYLYSINE-DEFEROXAMINE LINKER USED IN THIS LABORATORY HAS BEEN SHOWN TO WORK VERY WELL IN SIMILAR SYSTEMS, AND WILL BE APPLIED HERE. IN THE SCHEME WE PROPOSE WE HAVE TWO DISTINCT ROUTES FOR COUPLING POLYMER DOSIMETRY AND BIODISTRIBUTION ASPECTS WILL BE INVESTIGATED TO DETERMINE THE STABILITY OF OUR SYSTEM IN VIVO, TO EVALUATE DOSE DELIVERY TO TUMOR